Bipolar Disorder Therapeutics – Pipeline Assessment and Market Forecasts to 2018 – MarketWatch (press release)
|
Bipolar Disorder Therapeutics – Pipeline Assessment and Market Forecasts to 2018
MarketWatch (press release) In addition to this, pipeline molecules such as cariprazine, Nuvigil (armodafinil), and Latuda (lurasidone hydrochloride) are expected to be launched in 2013. GlobalData expects that these factors will account for positive growth within the bipolar … and more » |